Loading organizations...
§ Venture Capital · New York City, NY, USA
early-stage life science venture capital fund creating and investing in breakthrough biotechnology companies focused on therapeutics.
Inning One Ventures is an early-stage life science venture capital fund based in New York, New York, focused on creating and investing in breakthrough biotechnology companies. The firm has closed two funds as of February 2025 and made three documented investments to date, targeting innovative biotech startups with transformative potential across various therapeutic areas. Its most recent participation was in a $95 million Series C financing round for portfolio company Ajax Therapeutics in May 2024, led by Goldman Sachs Alternatives. Key personnel include Managing Partner Martin Vogelbaum, co-leads Lucas Nelson and Steve Berg, and Head of Life Sciences Investing Amit Sinha. While a specific founding year is not publicly available, Inning One Ventures operates as a newly launched venture firm.
Inning One Ventures has 1 tracked investment across 1 company. The latest tracked deal is $95.0M Series C in Ajax Therapeutics in May 2024.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| May 13, 2024 | Ajax Therapeutics | $95.0M Series C | Ming Cheah | Boxer Capital, EcoR1 Capital, ELI Lilly And Company, Point72, RA Capital Management, Schr"dinger, Vivo Capital |